)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ChemoMetec
ChemoMetec (CHEMM) investor relations material
ChemoMetec Q4 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 25/26 earnings summary11 Sep, 2026
Executive summary
Revenue reached DKK 511 million for FY 2025/2026, up 3% year-over-year (7% at constant FX), driven by strong instrument sales, especially XcytoMatic and NC-203.
EBITDA grew 9% to DKK 281 million, with margin rising to 55% due to higher revenue, improved profitability, and reduced staff costs.
Life science segment now represents 95% of revenue, growing 6% to DKK 485 million, while animal semen, beer, and milk declined 32% as the company exits these markets.
U.S. and Canada revenue declined 6% (up 1% at constant FX), Europe rose 14%, and rest of world grew 21%.
Strong balance sheet with DKK 290 million in cash and DKK 725 million in equity; share buyback program repurchased 1.2% of share capital.
Financial highlights
Instrument revenue increased 13%, led by XcytoMatic and NC-203, with XcytoMatic sales jumping from DKK 27.7 million to DKK 68.1 million.
Service revenue rose 4%, while consumables declined 4% due to the U.S. government shutdown and fewer patients treated.
Q4 instrument sales hit a record DKK 17.7 million, with over 50% from XcytoMatic and NC-203.
CapEx for the year was DKK 100 million, focused on software, automation, product development, and facilities.
Outlook and guidance
FY 2026/2027 revenue expected at DKK 545–575 million (7–13% growth), EBITDA at DKK 300–313 million.
CapEx guidance for FY 2026/2027 is DKK 120 million, reflecting ongoing investments in automation and software.
Growth expected to be driven primarily by instrument sales, especially replacements for NC-200 and increased demand for XcytoMatic.
Guidance does not include upside from potential Roche, Tecan, or Hamilton collaborations.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ChemoMetec
- Q3 revenue and EBITDA rose sharply, led by instruments and automation partnerships.CHEMM
Q3 25/26 - EBITDA margin rose to 55% as XcytoMatic sales grew 60% despite US market headwinds.CHEMMQ2 25/26
- 8% revenue growth and 11% EBITDA rise driven by XM/XcytoMatic platform and automation demand.CHEMMQ1 25/26
- Q3 revenue up 26% and EBITDA up 59%, with strong North American growth and robust margins.CHEMMQ3 19/20
- Strong growth, high margins, and major automation investments drive positive outlook.CHEMMQ4 24/25
- Q1 revenue up 27% and EBITDA up 50%, driven by robust instrument sales and new launches.CHEMMQ1 24/25
- Revenue and profit declined, but new product launches and automation drive 2024/25 growth outlook.CHEMMQ4 23/24
- Q3 revenue up 26% and EBITDA up 47%, with guidance unchanged amid global uncertainties.CHEMMQ3 24/25
- Strong H1 growth and Ovizio acquisition position ChemoMetec for continued innovation.CHEMMQ2 24/25
Next ChemoMetec earnings date
Q1 26/276 Nov, 2026
ChemoMetec
Next ChemoMetec earnings date
Q1 26/276 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Producer of cell counting and analysis systems
ChemoMetec is a Danish biotech company that specializes in the development and production of cell counting and analysis systems for use in the life sciences industry. The company was founded in 1997 and has since become a leading provider of advanced cell analysis solutions to customers around the world. Some of ChemoMetec’s competitors include Thermo Fisher, MERCK, and GE Healthcare.
The business model
ChemoMetec's business model is based on providing high-quality, reliable, and easy-to-use cell analysis systems that enable researchers to obtain accurate and reproducible results. The company's products include the NucleoCounter and NC-202 instruments, which are used by researchers in a variety of applications, including drug discovery, cancer research, and stem cell research.
How ChemoMetec makes money
ChemoMetec generates revenue primarily through the sale of its cell analysis systems, as well as through ongoing customer support and service contracts. The company's revenue is also generated through its partnerships with other biotech and life sciences companies, as well as through collaborations with academic research institutions.
Accurate cell counting and analysis
ChemoMetec's cell analysis systems have gained a reputation for their accuracy and reliability, with a high degree of precision in cell counting and analysis. The company has also been recognized for its user-friendly approach to design and software, making their systems easy to operate and accessible to a wide range of researchers.